Fiscal Year End June 2026 Financial Summary (Japanese GAAP) (Consolidated)

Performance Summary

This financial summary reports the consolidated results of the Koa Shōji Group for the period ending June 2026, consisting of two main business lines: API sales and pharmaceutical manufacturing and sales. Net sales were 24,678 million yen, up 6.1% year over year. Operating income was 5,476 million yen, up 2.3%; ordinary income was 5,521 million yen, up 2.7%; and net income attributable to owners of the parent was 3,748 million yen, up 3.0%, reflecting stable growth. An earnings briefing is scheduled for August 7. The mid-term plan outlines growth strategies through earlier operation of the Kazo Dai-ni Factory and expansion of API sales, with a full-year outlook for June 2027 of net sales 26,700 million yen, operating income 5,270 million yen, and net income 3,590 million yen.

Outlook and Strategy

The long-term plan targets 2030, continuing to evolve API sales toward a specialized pharmaceutical trading company and manufacturing and sales toward a top producer focused on injectable products. Accelerating the operation of the Kazo Dai-ni Factory will reinforce fill-finish production capacity and aim to win new outsourcing contracts. The mid-term plan includes diversification of the supply chain, use of DX/AI, strengthened quality control, ESG initiatives, and enhanced group synergies.